

INVESTOR PRESENTATION NOVEMBER 2019

Disclaimer

Forward Looking **Statement**

This Presentation contains forward-looking statements that relate to the Company's current expectations and views of future events and should be read together with the more detailed information and financial data and statements available on the Company's SEDAR profile at SEDAR.com. This Presentation does not contain all of the information you should consider before purchasing securities of the Company.

In some cases, these forward-looking statements can be identified by words or phrases such as "may", "might", "expect", "anticipate", "estimate", "intend", "plan", "indicate", "seek", "believe", "predict" or "likely", or the negative of these terms, or other similar expressions intended to identify forward-looking statements. The Company has based these forward-looking statements on its current expectations and projections about future events and financial trends that it believes might affect its financial condition, results of operations, business strategy and financial needs. These forward-looking statements include, among other things, statements relating to: the Company's expectations regarding its revenue, expenses and operations; The Company's expectations regarding timing of the completion of the construction; the Company's anticipated cash needs and its needs for additional financing; the Company's intention and ability to grow the business and its operations; including its ability to complete research and development acquisitions and integrate acquired businesses; the Company's expectations regarding harvesting of product and product sales prices; expectations with respect to future production costs and capacity; expectations regarding our growth rates and growth plans and strategies; expectations with respect to the approval of the Company's cannabis licences; expectations with respect to the future growth of its medical and recreational cannabis products in any jurisdiction, the Company's expected business objectives for the next twelve months; the Company's expectations with respect to international developments and initiatives; the Company's plans to develop cannabis greenhouses in Québec and Ontario; and the Company's expectations in respect to hemp based beverages in the United States of America.

Forward-looking statements are based on certain assumptions and analyses made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate and are subject to risks and uncertainties. In making the forward looking statements included in this Presentation, the Company has made various material assumptions, including but not limited to (i) obtaining the necessary regulatory approvals; (ii) that regulatory requirements will be maintained; (iii) general business and economic conditions; (iv) the Company's ability to successfully execute its plans and intentions; (v) the availability of financing on reasonable terms; (vi) the Company's ability to attract and retain skilled staff; (vii) market competition; (viii) the products and technology offered by the Company's competitors; and (ix) that our current good relationships with our suppliers, service providers and other third parties will be maintained. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect, and we cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, prospective purchasers of the Company's securities should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Company's expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including those listed under "Risk Factors" filed under the Company's SEDAR profile at SEDAR.com.

The Company's forward-looking statements are based on the reasonable beliefs, expectations and opinions of management. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There is no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. We do not undertake to update or revise any forward-looking statements, except as, and to the extent required by, applicable securities laws in Canada.



The Green Organic Dutchman™

Establishing the leading global organic cannabis brand



CERTIFIED ORGANIC

High quality organic cannabis grown in living soil with established proprietary organic growing techniques and leading-edge intellectual property



LEADING INNOVATION & IP

Exclusive licensing deals in Canada and select international markets with best-in-class technology with proven in-market results



STATE-OF-THE-ART FACILITIES

Production capacity coming online in phases timed with market growth and consumption. 1,476,000 sq. ft. hybrid greenhouses and processing facilities planned in Canada and over 167,000 sq. ft. planned internationally across

Europe and Jamaica



CONSUMER DRIVEN PORTFOLIO

Focused on providing a suite of premium consumer preferred products with various delivery methods for dried flower, oils and soon beverages, edibles, and topical creams



PROVEN MANAGEMENT TEAM


Experience in executive and operational management specific to consumer-packaged goods, horticulture, beverages, brand building, pharma, retail, international markets and cannabis



INTERNATIONAL SCALE

International growth initially through the United States, Poland, Jamaica, Denmark, and Mexico; continuously exploring additional international opportunities





DISCOVER ORGANIC

Largest certified organic producer in the Industry



Organic Advantage

Largest certified organic producer in the Industry



PREMIUM PRICE Industry non-organic average of \$10.26 per gram₍₁₎ vs \$15.92, or a **55% organic premium**₍₂₎



CERTIFIED ORGANIC INPUTS

Exposure to certain chemicals/ pesticides have been **proven to have adverse effects** on consumers health₍₄₎



CONSUMER PREFERENCE

Organic cannabis is preferred by **61%** of medicinal patients and **50%** of recreational cannabis consumers(3)

Pro-Cert's certification programs are ISO 17065 compliant and accredited, providing **global recognition and international access to the products and brands they certify**





(2) ORGANIC INDSUTRY AVERAGE ON, SK, NS RECREATIONAL SALES
CHANNEL [EXCLUDES SALES TAX, INCLUDES EXCISE TAX]
(3) HILL+KNOWLTON STRATEGIES – FEBRUARY, 2019 ONLINE
SURVEY RESEARCH
(4) SOURCE: LA WEEKLY "CANNABIS CONCENTRATES HAVE A
PROBLEM WITH PESTICIDES" 02/27/17







Canadian Facilities

1.4 million square feet of state-of-art purpose-built organic cultivation facilities



Canadian Facilities

Constructing some of the world's largest **state-of-the-art organic cannabis facilities**



ANCASTER CAMPUS - ONTARIO, CANADA 166,000 sq. ft. 17,500 KG [capacity] 12,000 KG [2020]

- All growing zones fully licensed by Health Canada; new processing facility licence amendment submitted in Q4 2019
- Includes co-gen power plant to **reduce power costs**
- Health Canada cultivation, sales, oil extraction and oil sales renewed until 2022
- EU GMP certification process underway which will enable exports to Europe



VALLEYFIELD CAMPUS - QUEBEC, CANADA 1,310,000 sq. ft. 185,000 KG [DESIGN] 10,000 KG [2020]

- **6 zones nearing completion** majority of capital required covered by restricted cash on hand
- Structure for phase 2 and 3 largely completed; **flexibility to quickly increase capacity** as the market develops

PHASED EXPANSION
FOR AGILE CAPACITY
MANAGEMENT

PHASE 1 10,000 KG up to

PHASE 3 65,000 KG

PHASE 4 55,000 KG

Q4 2019



Rightsized Production

Providing scalability while maintaining path to near-term profitability

Due to changing market conditions, TGOD has decided to adopt a new construction and operating plan, enabling agile capacity management. The Company took a number of actions to adapt to slower legal market conversion while remaining on track to achieve positive operating cash flow by Q2 2020.

- Reduced financing requirements
- Scaled back SG&A to focus on Canadian operational readiness in production, sales and Cannabis 2.0
- Rightsized near-term production to capture the organic segment while avoiding excess capacity
- Maintain optionality to quickly accelerate and expand production as the market develops
- \$50M to \$80M required between now and Q2 2020 to execute the plan

Annualized flower target capacity	Ancaster	Valleyfield	
Campus Current	17,500 KG	-	
Phase 1 Hybrid Greenhouse [6 zones - cultivation]	-	10,000 KG	
Phase 2 [18 zones – cultivation] + processing centre		55,000 KG	
Phase 3 [Rooftop Hybrid Greenhouse]	-	65,000 KG	
Phase 4 Third Hybrid Greenhouse	-	55,000 KG	
Campus Complete	17,500 KG	185,000 KG	
	Target flower production in		

2020: 20,000 KG – 22,000 KG

Ancaster

- Expected to be fully completed by the end of Q4 2019, including the processing facility
- Planned production of 12,000 kg in 2020, on path to mature scale capacity of 17,500 kg

Valleyfield

- Project demarcated into smaller phases
- Initial 6 zones will be completed with majority of capital covered by restricted cash on hand
- Four zones allocated for growing, one for mother plants and vegetation, and one for primary processing
- Production will be transported for finished goods processing at Ancaster
- Building envelope and roofing will be completed for the remaining 18 zones and the processing facility to secure the site against winter weather
- Maintains optionality to recommence completion of remaining 18 zones, bringing annual planned production to 65,000 kg, and Phase 3 for a further 65,000 kg



Hybrid Greenhouses Advantage

Purpose built with the environment and sustainable practices in mind

HIGH-QUALITY

Advanced humidity, temperature and environmental controls relative to conventional greenhouses enables operational optimization and maximizes plant health.



LOW-COST

Natural light availability & facility automation enables lower costs. Ancaster campus has an on-site co-gen power plant, significantly lowering operation costs.

Valleyfield, Quebec site benefits from North America's lowest power rates.



SUSTAINABLE

Using living soil and built to LEED certification standards, **TGOD** is able to significantly minimize its environmental impact vs traditional cannabis growing operations.





Cannabis 2.0

Portfolio of value-added products begin launching in December 2019























Consumer Packaged Goods

Value-added products to increase margins



MEDICAL MARKET

Expansion of partnerships with clinics across Canada with differentiated certified organic positioning

Execute allied health pilot program to maximize appropriate patient referrals to TGOD partners

Expand reach with cannabis clinic partners, physicians, and nurses across Canada with strategic key account management

Currently 25 clinic partner contracts in place covering 40 physical locations across Canada with more to come









RECREATIONAL MARKET

Best-in-class sales distribution via Velvet Management Inc.

Supply to the Ontario Cannabis Retail Corp [OCS]

Cannabis supply agreements with **The BC Liquor** Distribution Branch [BCLD] & The Alberta Gaming, Liquor and Cannabis Commission [AGLC] in place

Expect remaining provinces to start selling **TGOD brand** early 2020 as sufficient product supply becomes available

Product Roadmap

Consumer inspired and concept tested to ensure clear differentiation(*)



FLOWER

Unite Organic LA Confidential Indica dominant 3.5q, 5q formats

Harmony Organic

Skunk Haze Balanced 1:1 3.5g, 5g formats

Tranquility Organic

Zombie Kush Indica dominant 3.5g, 5g formats (Medical)

Discover Organic

Chocolope Sativa dominant 3.5g, 5g formats (Medical)



OIL

Unite Organic 25mg/ml [THC] < 1mg/mL [CBD] 30mL format

Harmony Organic

10mg/mL [THC] 16mg/mL [CBD] 30mL format

Care Organic

<1mg/mL [THC] 25mg/mL [CBD] 30mL format (Medical)

Care Organic

<1mg/mL [THC] 15mg/mL [CBD] 30mL format (Recreational)



VAPES*

Unite Organic 400mg [THC] < 1mg [CBD]

Harmony Organic 125mg [THC] 125mg [CBD]

Care Organic
<1mg [THC] 250mg [CBD]

Battery and USB

One time purchase kit

INFUSERS*

Dissolvable THC Powder 10mg [THC]

< 1mg [CBD] Single pack format

Dissolvable CBD Powder

1mg [THC] 10mg [CBD] 10-pack format

Dissolvable THC:CBD Powder

2.5mg [THC] 5mg [CBD] 4-Pack

TEAS*

Happy Hibiscus Maté

Energize and focus 2.5mg [THC/sachet] 5mg [CBD/sachet] 4-pack format

Zen Green Sencha

De-stress and relax 1.0mg [THC/sachet] 10mg [CBD/sachet] 10-pack format

Restful Chamomile

Restful Chambinne Restful sleep 2.5mg [THC/sachet] 5mg [CBD/sachet] 4 pack format

FUTURE LAUNCHES*

Capsules, pre-rolls sports recovery, RTDs, hemp oil capsules, topicals.



*UPON HEALTH CANADA APPROVAL OF CO-PACKERS FACILITIES





Research & Development

Designed to generate diverse product offerings, competitive claims & intellectual property



R&D Leadership Team

Experienced team with significant Pharma, Agriculture, Cannabis and CPG Experience



RAV KUMAR, PHD, B.Sc. CHIEF SCIENCE OFFICER

Prior to joining TGOD, Dr. Kumar was Managing Director of Apotex India. Dr. Kumar has over 25 years' experience in the pharmaceutical industry and is a seasoned senior executive with international experience in Europe, Asia and North America. Dr. Kumar held senior leadership roles with GlaxoSmithKline, including VP R&D Operations and Business Dev. Classic Brands. Dr. Kumar received the 2014 Award for Leadership in Canadian Pharmaceutical Sciences.



PREM VIRMANI, M.Sc., B.Sc. CHAIR OF BEVERAGE SCIENCE

Mr. Virmani is the former SVP of Global Science and Research for Cott Beverages, Inc. Inducted into the Private Label Hall of Fame in 2018, Mr. Virmani has led development in every major beverage category, including the Sam's Choice cola program for Walmart, President's Choice Cola for Loblaws, as well as major private label brands for Publix, Wegmans and Safeway. Mr. Virmani began his career with Coca-Cola and is known as the Pioneer of the Private Label soft drink industry.



KEVIN CANNING, PHD, MBA
VP, SCIENCE STRATEGY, PORTFOLIO & OPERATIONS

Dr. Canning brings over 15 years in healthcare leadership roles with GlaxoSmithKline Canada & China. Dr. Canning's experience includes basic research and genetics, research alliances/scouting for global R&D pipeline, venture capital, clinical research, epidemiology, medical affairs, project management and outsourcing. Dr. Canning holds a Ph.D. and an H.B.Sc. in Physiology, both from Western University. He also holds an M.B.A. from the Ivey Business School, Western University and was recognized as an Ivey Scholar.



DAVID BERNARD PERRON, M.Sc.

VP, GROWING OPERATIONS

Mr. Bernard-Perron is an Agrologist with a Master of Science degree from McGill University specializing in Plant Sciences and Organic Agriculture. Mr. Bernard-Perron began his career working in greenhouse production in 2001 at the McGill Greenhouses and Horticultural Research Centre. He was responsible for leading Whistler Medical Marijuana Corporation through organic certification, becoming the first fully certified organic licensed producer.



AMYN SAYANI, PHD
VP, R&D MEDICAL OPERATIONS

Dr. Sayani comes to TGOD after 20 years at GlaxoSmithKline where he worked in various roles across the drug development and commercialization continuum, including product development, regulatory and medical affairs, health outcomes research and real world evidence, and market access. Dr. Sayani has authored numerous publications and patents and has led various projects to optimize patient access to new medicines. Dr. Sayani is a pharmacist by training, and has a PhD in Pharmaceutical Sciences (Rutgers University), and a Masters of Science in Health Research Methodology (McMaster University, Ontario).



R&D Strategy

Develop differentiated products and competitive claims





HUMAN STUDIES &

Observational data

speed of onset,

certain diseases

collection and mining,

bioavailability, effect on

CLAIMS





PLANT SCIENCES

Yield improvement, strategic loss prevention and strain development

EXTRACTION & PROCESSING

Science-driven approach for enhanced efficiency and quality

CANNABINOID & TERPENE OPTIMIZATION

Characterization, analysis, blending & optimization

NEW PRODUCT DEVELOPMENT

Edibles such as capsules, beverages, novel formulations and dosage forms


















REGULATORY SUBMISSIONS & APPROVALS

Canada, Mexico [Medical] and other international markets

COMMERCIAL SUPPORT

Organic differentiation, educational materials, external engagement, science advisory board, innovation hub, new business development opportunities







International Footprint

International growth initially through operations in the **United States, Poland, Denmark, Jamaica and Mexico**; TGOD continues to explore strategic international opportunities



Beverage Innovation

Nature amplified by science

CALIFORMULATIONS

TGOD has partnered with multi-billion-dollar ingredient giant Symrise and a management team of seasoned beverage experts to create Califormulations LLC., a US based beverage innovation company.

Califormulations provides global branded companies with concept-to-shelf beverage commercialization support, including formulation development, technical services, in-house pilot scale production, and contract manufacturing co-ordination.

Focus on hydration and functional beverages, utilizing advanced processing capabilities – hot or cold fill, carbonation, and homogenization.











HemPoland

Market Leader within the **European CBD/Hemp Industry**











FIRST MOVER ADVANTAGE

Established in 2014, HemPoland, a wholly owned subsidiary of TGOD, was Poland's first **company** to obtain a state license for hemp cultivation and CBD oil derivatives. They are one of the few to have designed and optimized supercritical carbon dioxide extraction equipment dedicated specifically to hemp fibres.



INNOVATION

Conducted extensive genetic research on multiple hemp strains. Identified best practices in order to obtain the highest quality hemp extracts containing phytocannabinoids, a key differentiator for HemPoland's CannabiGold and Terpenes+ product lines.

Plays an integral role as part of TGOD's Global Strategic Hemp Division, sharing IP with our global network of partners.



EXPANDING DISTRIBUTION

Established distribution channels in **Poland** and **Germany**, launching in the **UK** in Q4 2019 and expanding to additional markets as local regulations allow.



International Joint Ventures

Planting seeds for future growth

DENMARK: TGOD GENETICS & KNUD JEPSEN

Founded in 1939, Knud Jepsen is the world's largest Kalanchoes breeder selling more than **35 million plants and 90 million** cuttings to over 75 countries

Over **80 years of operational experience** in all areas of horticulture, including genetics, breeding, international partnerships and established global distribution networks

Licensed by Danish Medicines to conduct research and development related to the **creation of elite cannabis genetics**

TGOD Genetics JV aims to develop and patent innovative and commercially valuable elite cannabis genetics





50/50 joint venture with LLACA Grupo Empresarial; entering the Mexican medical cannabis market [and potentially the recreational market upon legalization]

Proprietary distribution capabilities and access to premier distributors with established commercialized pharmaceutical and over-the-counter products

LLACA has access to patients and consumers through **7,600 retail locations**: **4,500 pharmacies and 3,100 supermarkets**

Jamaican Market Leadership

Epican Medicinals is vertically integrated with licences for cultivation, extraction, manufacturing, and retail distribution

HISTORIC ACHIEVEMENT

Epican was granted Jamaica's first cultivation license [October 2017], and is now the first fully integrated company to have obtained two retail licences from Jamaica's Cannabis Licensing Authority (CLA)

TGOD owns 49.18% of Epican Medicinals

FOOTPRINT

Two cultivation sites with current capacity of 1,300 KG, planned full capacity 14,000 KG

COMPETITIVE ADVANTAGE

The strategic partnership creates a platform to export TGOD branded, Jamaican grown cannabis products to select international medical markets.

DISPENSARIES OPEN

Kingston [July 2018] Montego Bay [May 2019]

Additional planned dispensaries:

Negril, Ocho Rios, Falmouth







Environment, Social & Governance

A comprehensive sustainability and governance focus



ESG

A comprehensive sustainability and governance focus



LED lighting system

Rainwater recapture basin

Leadership in organic agriculture associations

Recyclable packaging

Use of renewable **hydroelectricity** in Quebec

Built to **LEED Certification** standards

Reusing soil leads to significantly **less waste to landfill** vs industry

Best-in-class carbon filtration, **preventing odour pollution**



Employee volunteer program

Community organic farm

Blackout blinds to prevent night time light pollution

Community engagement and outreach University/college relationships



TGOD employees volunteer on a Saturday to cleanup the Hamilton shoreline as part of the company's "Rooted in the Community" program.



COMMITMENT TO STRONG CORPORATE GOVERNANCE

Majority independent board of directors, including Chair Strong and independent quality assurance team

SAP integration

Strong culture of **compliance and ethics**



Management

Experience in executive and operational management specific to consumer packaged goods, beverages, brand building, pharmaceutical, retail, international markets and cannabis



Management Team

Combined 200+ years of expertise in Cannabis, Pharmaceutical, Retail, Beverage and Consumer Packaged Goods



BRIAN ATHAIDE CEO & DIRECTOR

28+ years of global executive experience including CFO and Executive Vice President, Human Resources and Information Technology of Andrew Peller Limited, a publicly listed Canadian wine producer. Mr. Athaide has also held various positions in finance, including Chief Financial Officer at a number of international divisions of Procter & Gamble, a leading consumer products company. He has a Bachelor of Commerce degree, with a major in finance and marketing from McGill University.



CSABA REIDER PRESIDENT

35+ years executive experience in the consumer-packaged goods industry including VP at Cott Corporation, and President & CEO of XYIENCE Inc. Mr. Reider has served on the Board of several companies including food & beverage conglomerate Associated Brands.



SEAN BOVINGDON

30+ years finance experience across a multitude of private and public companies and industries including CFO of Toronto Hydro Corporation. Mr. Bovingdon served as President & CFO as well for public and private oil and gas companies, Mr. Bovingdon has been involved in \$1.1bn of public equity and debt financings, and \$2bn of syndicated credit facilities, including three IPOs.



MIKE GIBBONS VP.SALES

25+ years of consumerpackaged goods experience in the food and beverages sector. Mr. Gibbons spent over 15 years with Cott Corporation in roles of increasing responsibility, from Sr. Vice President, Sales to President of the US business unit. Mr. Gibbons has experience in both branded and private label businesses, and led highperforming teams in geographic expansion, building distribution and new product distribution.



MARIE-JOSÉE LAFRANCE VP. HUMAN RESOURCES

25+ years experience in the fast paced competitive retail consumer goods and health sectors with Laura Canada. Holt Renfrew and McKesson Canada. She joined Laura Canada at it's infancy and was an instrumental contributor to the rapid and successful growth of it's business across Canada. At McKesson Canada, Marie-Josée led the successful integration of new retail banners across the board and the deployment of a Shared Services model. She brings extensive experience in Human Resources, M&A. and change management.



MATT SCHMIDT EXECUTIVE VP. CORPORATE DEV.

Mr. Schmidt was a Vice President of Investment Banking at one of Canada's independent investment banks. during which time he became a specialist in the Canadian cannabis sector. Mr. Schmidt holds a Master of Business Administration from Wilfrid Laurier University (Waterloo, Ontario) and a Bachelor of Commerce (Honours) from the University of Windsor.



ANNA STEWART

VP. GENERAL COUNSEL AND CORPORATE SECRETARY

Mrs. Stewart brings a wealth of corporate in-house and private practice legal experience to TGOD. Most recently, Mrs. Stewart was Assistant General Counsel of Teva Pharmaceutical Industries Ltd. [Canadian Division]. Prior to Teva, Ms. Stewart practiced corporate law at a prominent national Canadian law firm. Ms. Stewart has extensive experience in regulated products manufacturing. marketing and distribution, intellectual property licensing and complex M&A activities.



JOHN WREN

VP. GROWING OPERATIONS

22+ years at Cott Corporation, most recently as VP Operations, Mr. Wren was responsible for the operation of seven beverage facilities across North America. More recently, Mr. Wren was with Monaghan Mushrooms Ltd., a 270-acre farm operation where his team grew and packaged fresh mushrooms.

Board Of Directors

Seasoned, majority independent board of directors



JEFF SCOTT CHAIRMAN

Mr. Scott is President of Postell Energy Co., a private Canadian oil producer in business in western Canada since 1980. Mr. Scott is the Founder and was Chairman of Gran Tierra Energy, a South American based E&P Company from 2004 to June of 2015. Mr. Scott is also Chairman of Sulvaris Inc., a private fertilizer technology company created in February 2012. He has extensive management, financing, mergers & acquisitions, and public company experience. Over the past 20 years he has been involved in a variety of capacities from founder to officer and/or director in numerous publicly traded companies.





BRIAN ATHAIDE CEO & DIRECTOR

28+ years of global executive experience including CFO and Executive Vice President, Human Resources and Information Technology of Andrew Peller Limited, a publicly listed Canadian wine producer. Mr. Athaide has also held various positions in finance, including Chief Financial Officer at a number of international divisions of Procter & Gamble, a leading consumer products company. He has a Bachelor of Commerce degree, with a major in finance and marketing from McGill University.



MARC BERTRAND INDEPENDENT DIRECTOR

Mr. Bertrand is a seasoned consumer products executive with three decades of success in brand building, strategic licensing, international markets and manufacturing. Previously President & CEO of the Mega Bloks brand, which was sold to Mattel in 2014 for over \$500 million dollars. Developed strategic licence agreements with several of the world's most iconic entertainment franchises including Disney, Nickelodeon and Marvel.



DR. CAROLINE MACCALLUM INDEPENDENT DIRECTOR

Dr. MacCallum is one of the world's most prominent experts in cannabinoid-based medicine. Dr. MacCallum is an internist, complex pain and cannabinoid clinician. researcher, and clinical instructor in the department of medicine, an adjunct prof. in the faculty of pharmaceutical sciences program and an associate member of the department of palliative care at the University of British Columbia. Dr. MacCallum is the medical director at GreenLeaf Medical Clinic, where she has assessed and developed cannabinoid treatment plans for more than 3,000 patients across Canada.



JACQUES DESSUREAULT INDEPENDENT DIRECTOR

Mr. Dessureault is a senior executive with extensive pharmaceutical experience, specifically from life sciences, over-thecounter, natural health and technology industries. He has held both international and domestic roles with Novartis, as global marketing division head as well as business unit head and general manager, additionally domestic senior executive roles as president and general manager of Valeant Pharmaceutical Inc., vice-president at Bristol Myer-Squibb. Mr. Dessureault is a strategic advisor with the casting and performance group of Cirque du Soleil.



NICHOLAS KIRTON INDEPENDENT DIRECTOR

Mr. Kirton is a professional accountant. He spent thirty-eight years with KPMG LLP where he was elected to Partner in 1976. Subsequent to his retirement, Mr. Kirton has served on the boards of a total of eight reporting issuers, in most cases as Chair of the Audit Committee. Additionally, Mr. Kirton served as Chair of the Board of the Canadian Investor Protection Fund.



Financials

Well positioned to have industry leading margins



Capitalization Table

Cash On Hand & Securities Outstanding as of September 30th, 2019

TYPE		\$ MILLIONS			<u>Secu</u>	<u>ırities</u>
Cash On Hand		\$23				FULLY
Restricted Cash [For			SHAREHOLDERS	AMOUNT (#)	BASIC	DILUTED
Construction]		\$40	TOTAL COMMON SHARES			
TOTAL		\$63	(BASIC)	275,877,244	100%	76%
Options Outstanding			Warrants	64,247,628		18%
Various Prices from			Options	17,817,133		5%
\$0.50 - \$6.91	17,817,133		Escrowed/Contingent Shares	5,144,468		1%
WARRANTS OUTSTANDING			TOTAL COMMON SHARES			
(Expiry)	AMOUNT (#)	<u>AMOUNT</u>	FULLY DILUTED	363,086,473		100%
\$3.00 [TGOD.WT] (28FEB21)	34,607,765	100,823		203,000, 110		10070
\$7.00 (02MAY20)	15,092,363	105,647				
\$9.00 (19APR21)	12,592,500	113,333				
\$9.50 (26JUN21)	1,955,000	18,573				
TOTAL WARRANTS	64,247,628	\$338,376				





Comparables

Enterprise Value Revenue, EBITDA CY 2020, CY 2021 multiples relative to peers

	EV/ REVENUE		EV/EBITDA	
CANADIAN LPs	2020	<u>2021</u>	<u>2020</u>	<u>2021</u>
Tilray	7.7x	5.0x	nmf.(2)	35.3x
Canopy	7.9x	4.7x	nmf. (3)	103.3x
Cronos	11.1x	5.7x	nmf. (4)	35.3x
Aurora	7.3x	4.2x	93.2x	22.6x
HEXO	2.3x	1.2x	18.5x	6.0x
Organigram	3.1x	2.2x	8.7x	5.6x
Aphria	2.1x	1.6x	10.6x	5.9x
Supreme	1.6x	N/A	6.5x	3.8x
TGOD	1.2x	0.5x	36.8x	3x
Peer Group Average	5.4x	3.5x	28x	27.3x
TOP U.S. MSOs				
Curaleaf	3.3x	2.0x	11.3x	6.7x
Cresco	4.0x	2.5x	13.9x	8.4x
Green Thumb	4.1x	2.8x	16.0x	9.1x
Charlotte's Web	5.0x	3.3x	14.7x	10.0x
Trulieve	3.0x	2.3x	7.8x	5.7x



Owen Bennett P: +44 (0)2070298431



Derek Dley P: (416) 869-7270



Brett Hundley P: +1 (804) 939-5268

TGOD is looking to increase analyst coverage and institutional ownership







Chris Carey P: (646) 743-2110



TGOD has applied for listing on the NASDAQ Capital Market

I) BMO CANNABIS TRADING ACTIVITY REPORT OCTOBER 25th, 2019 (2) ESTIMATE OF (\$36mm) CY2020 (3) ESTIMATE OF (\$162mm) CY2020 (4) ESTIMATE OF (\$33mm) CY2020

The Green Organic Dutchman™

Establishing the leading global organic cannabis brand



CERTIFIED ORGANIC

High quality organic cannabis grown in living soil with established proprietary organic growing techniques and leading-edge intellectual property



LEADING INNOVATION & IP

Exclusive licensing deals in Canada and select international markets with best-in-class technology with proven in-market results



STATE-OF-THE-ART FACILITIES

Production capacity coming online in phases timed with market growth and consumption. 1,476,000 sq. ft. hybrid greenhouses and processing facilities planned in Canada and over 167,000 sq. ft. planned internationally across

Europe and Jamaica



CONSUMER DRIVEN PORTFOLIO

Focused on providing a suite of premium consumer preferred products with various delivery methods for dried flower, oils and soon beverages, edibles, and topical creams



PROVEN MANAGEMENT TEAM

Experience in executive and operational management specific to consumer-packaged goods, horticulture, beverages, brand building, pharma, retail, international markets and cannabis



INTERNATIONAL SCALE

International growth initially through the United States, Poland, Jamaica, Denmark, and Mexico; continuously exploring additional international opportunities







CONTACT US

Want to learn more? We would love to chat

CLIENT CARE

[T]: 905 - 304 - 4201 [E] info@tgod.ca

MEDIA RELATIONS

Sebastien Bouchard

Director of Communications [T]: 647-272-2476

[E]: sbouchard@tgod.ca

INVESTOR RELATIONS

Shane Dungey

Vice President, Investor Relations

[E]: sdungey@tgod.ca

[T]: 905 – 304 – 4201 Ext. 336

[E]: invest@tgod.ca

EXCHANGE LISTINGS

TSX: TGOD | TGOD.WT US: TGODF | TGODWF

GR: O1GA

MAILING ADDRESS

6205 Airport Road, Building A #301 Mississauga, Ontario L4V 1E3









